Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

Ambient air pollution, hot and cold temperature extremes and other factors associated with climate change are likely ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...

H.C. Wainwright analyst Arthur He raised the firm’s price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating ...

USA: Researchers have discovered in a new study that young children with moderate-to-severe atopic dermatitis (AD) tend to be ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Finding an effective, safe medication to control itch is essential to maximize patient comfort. Because Zenrelia does not require a loading dose and is administered once daily, Zenrelia may help impro ...

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...